Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | Director · Chief Development Officer | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,647 |
Reported balance
After 2026-06-11 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 61,647 · Balance 61,647 F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. |
| Common StockSEC Table I · non-derivative | Direct | 297,491 |
Reported balance
After 2026-06-12 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-06-12 · Grant · Acquired 232,417 · Balance 297,491 F4: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Matt and Alli Davidson Trust | 3,427 |
Reported balance
After 2026-06-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 3,427 · Balance 3,427 F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust. |
| Series A Preferred StockSEC Table I · non-derivative | Direct | 1,822.13 |
Reported balance
After 2026-06-11 transaction · row 4
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 1,822.13 · Balance 1,822.13 F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. |
| Series A Preferred StockSEC Table I · non-derivative | IndirectBy Matt and Alli Davidson Trust | 1,923.428 |
Reported balance
After 2026-06-11 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-06-11 · Grant · Acquired 101.298 · Balance 1,923.428 F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2036-06-12 | Direct | 232,417 |
Reported balance
After 2026-06-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-12 · Grant · Acquired 232,417 · Balance 232,417 F7: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.
F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.
F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.
F4: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.
F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.
F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.
F7: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verrica Pharmaceuticals Inc.
Report date September 05, 2019 · Filed September 09, 2019
Section 16 reporting ended · disclosed 2019-09-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,556,179 |
Ending reported balance
After 2019-09-09 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2019-09-05 · Sale · Disposed 3,100 · Balance 2,572,393 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2019-09-06 · Sale · Disposed 3,802 · Balance 2,568,591 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2019-09-06 · Sale · Disposed 4,712 · Balance 2,563,879 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2019-09-06 · Sale · Disposed 1,400 · Balance 2,562,479 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2019-09-09 · Sale · Disposed 6,300 · Balance 2,556,179 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F6: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 10:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 232,417 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001213900-26-069037 · ownership.xml · derivative · entry 6 Davidson Matt · CIK 0001741937 · Director · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,417 Underlying: Common Stock · 232,417 shares Expires 2036-06-12 F7 · kind: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. F7 · price: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. F7 · derivative.exercise_date: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 10:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 232,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · Director · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,491 F4 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 10:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantSeries A Preferred Stock | 101.298 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 5 Davidson Matt · CIK 0001741937 · Director · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Matt and Alli Davidson Trust Disclosed balance after: 1,923.428 F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3 · kind: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F5 · kind: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3 · price: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F5 · price: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. F6 · ownership.nature: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 10:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantSeries A Preferred Stock | 1,822.13 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · Director · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,822.13 F1 · kind: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F5 · kind: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. F1 · price: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F5 · price: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 10:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 3,427 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · Director · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Matt and Alli Davidson Trust Disclosed balance after: 3,427 F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3 · kind: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F3 · shares: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3 · price: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F6 · ownership.nature: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 10:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 61,647 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · Director · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,647 F1 · kind: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F1 · shares: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F1 · price: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. Read SEC document |
| September 09, 2019 Filed Sep 9, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 6,300 | $10.82 | $68,166.00 |
DisclosureSEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 5 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,556,179 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,400 | $12.07 | $16,898.00 |
DisclosureSEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,562,479 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 4,712 | $11.44 | $53,905.28 |
DisclosureSEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,563,879 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,802 | $10.38 | $39,464.76 |
DisclosureSEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,568,591 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,100 | $10.29 | $31,899.00 |
DisclosureSEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,572,393 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 21:23 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,188 | $10.14 | $22,186.32 |
DisclosureSEC source: 0001209191-19-047734 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,575,493 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.05 to $10.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2019 Filed Aug 29, 2019 21:23 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 500 | $10.23 | $5,115.00 |
DisclosureSEC source: 0001209191-19-047734 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577,681 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.05 to $10.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 21:20 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,773 | $10.21 | $28,312.33 |
DisclosureSEC source: 0001209191-19-045382 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,578,181 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:20 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,118 | $10.76 | $33,549.68 |
DisclosureSEC source: 0001209191-19-045382 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,580,954 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.48 to $11.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 21:20 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 422 | $10.28 | $4,338.16 |
DisclosureSEC source: 0001209191-19-045382 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584,072 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.07 to $10.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2019 Filed Aug 6, 2019 22:14 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,602 | $10.28 | $26,748.56 |
DisclosureSEC source: 0001209191-19-044881 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584,494 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 22:14 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,679 | $10.65 | $17,881.35 |
DisclosureSEC source: 0001209191-19-044881 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,587,096 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.28 to $10.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2019 Filed Aug 6, 2019 22:14 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,969 | $10.78 | $21,225.82 |
DisclosureSEC source: 0001209191-19-044881 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,588,775 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.25 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 21:41 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,953 | $11.97 | $23,377.41 |
DisclosureSEC source: 0001209191-19-044073 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,590,744 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.69 to $12.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 31, 2019 Filed Aug 1, 2019 21:41 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,500 | $12.02 | $42,070.00 |
DisclosureSEC source: 0001209191-19-044073 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,592,697 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.71 to $12.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 21:41 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 4,885 | $11.83 | $57,789.55 |
DisclosureSEC source: 0001209191-19-044073 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,596,197 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.72 to $12.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 23:57 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 630 | $12.52 | $7,887.60 |
DisclosureSEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,601,082 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.34 to $12.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 23:57 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 8,551 | $11.62 | $99,362.62 |
DisclosureSEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,601,712 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.13 to $12.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 23:57 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,902 | $10.65 | $20,256.30 |
DisclosureSEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,610,263 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.29 to $10.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 23:57 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 975 | $10.23 | $9,974.25 |
DisclosureSEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612,165 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 24, 2019 Filed Jul 24, 2019 23:13 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 502 | $10.19 | $5,115.38 |
DisclosureSEC source: 0001209191-19-043133 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,613,140 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 23, 2019 Filed Jul 24, 2019 23:13 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,600 | $10.28 | $16,448.00 |
DisclosureSEC source: 0001209191-19-043133 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,613,642 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 23:13 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 700 | $10.17 | $7,119.00 |
DisclosureSEC source: 0001209191-19-043133 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,615,242 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.10 to $10.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 19, 2019 Filed Jul 19, 2019 22:06 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,800 | $10.28 | $18,504.00 |
DisclosureSEC source: 0001209191-19-042811 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,615,942 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.12 to $10.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 22:06 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 6,700 | $10.27 | $68,809.00 |
DisclosureSEC source: 0001209191-19-042811 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,617,742 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.005 to $10.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 22:06 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,300 | $10.55 | $24,265.00 |
DisclosureSEC source: 0001209191-19-042811 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,624,442 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.435 to $10.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2019 Filed Jul 16, 2019 22:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,200 | $10.92 | $24,024.00 |
DisclosureSEC source: 0001209191-19-042276 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,626,742 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.71 to $11.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 22:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 5,290 | $10.89 | $57,608.10 |
DisclosureSEC source: 0001209191-19-042276 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,628,942 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.575 to $11.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 22:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,000 | $11.01 | $33,030.00 |
DisclosureSEC source: 0001209191-19-042276 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,634,232 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.77 to $11.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 11, 2019 Filed Jul 11, 2019 21:19 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,640 | $11.16 | $18,302.40 |
DisclosureSEC source: 0001209191-19-041852 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,637,232 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.09 to $11.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2019 Filed Jul 11, 2019 21:19 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 9,105 | $11.57 | $105,344.85 |
DisclosureSEC source: 0001209191-19-041852 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638,872 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.16 to $12.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 21:19 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,467 | $11.88 | $29,307.96 |
DisclosureSEC source: 0001209191-19-041852 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647,977 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.39 to $12.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 08, 2019 Filed Jul 8, 2019 20:55 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 5,675 | $11.06 | $62,765.50 |
DisclosureSEC source: 0001209191-19-041426 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,650,444 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.83 to $11.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 05, 2019 Filed Jul 8, 2019 20:55 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,954 | $11.41 | $45,115.14 |
DisclosureSEC source: 0001209191-19-041426 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,656,119 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2019 Filed Jul 8, 2019 20:55 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,900 | $11.50 | $33,350.00 |
DisclosureSEC source: 0001209191-19-041426 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660,073 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.01 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2019 Filed Jul 2, 2019 21:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 6,239 | $11.57 | $72,185.23 |
DisclosureSEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,662,973 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.32 to $12.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 15,421 | $12.00 | $185,052.00 |
DisclosureSEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,669,212 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.62 to $12.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 21:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 8,359 | $11.41 | $95,376.19 |
DisclosureSEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684,633 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.01 to $11.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 21:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,502 | $10.63 | $37,226.26 |
DisclosureSEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,692,992 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 22:11 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 210 | $10.04 | $2,108.40 |
DisclosureSEC source: 0001209191-19-039343 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,696,494 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 21:34 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,431 | $10.03 | $14,352.93 |
DisclosureSEC source: 0001209191-19-037224 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,696,704 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:34 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 700 | $8.86 | $6,202.00 |
DisclosureSEC source: 0001209191-19-037224 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,698,135 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.775 to $8.905, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 22:06 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 838 | $8.89 | $7,449.82 |
DisclosureSEC source: 0001209191-19-036181 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,698,835 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.74 to $8.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:06 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,100 | $8.79 | $18,459.00 |
DisclosureSEC source: 0001209191-19-036181 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,699,673 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.275 to $9.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.